Cellectis reveals POC for smart T-cells that recognize tumors
Category: #health  By Mateen Dalal  Date: 2019-11-15
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Cellectis reveals POC for smart T-cells that recognize tumors

Cellectis, a French biopharmaceutical company that aims to innovate immunotherapies based on gene-edited allogeneic CAR T-cells, recently revealed a report issued in Nature Communications that explains a proof-of-concept (POC) for cell pathway’s rewiring to produce extremely intelligent T-cells which could identify cancerous tumors and create a micro secretion of therapeutic proteins.

This advancement could eventually enhance the capability of T-cells to fight cancer and redesign the tumor microenvironment. Moreover, by using gene editing procedures to rewire the CD25, PD1 and TCRα genes, the study allowed CAR T-cells to micro secrete the IL-12, pro-inflammatory cytokine, in a tumor.

Reportedly, this procedure was done in a time-dependent manner which would further lay the foundation for the next generation of highly active, potentially safer and tightly controlled CAR T-cell therapies.

Speaking on the move, Dr. Philippe Duchateau, Ph.D., Chief Scientific Officer, Cellectis, said that the conversation near the tumor microenvironment has become a trending issue in the CAR T-cell space, and with the current developments in gene-editing technologies, particularly TALEN®, has opened the possibility to manipulate T-cell’s way to regulate itself to adjust with its environment.

Duchateau added that, with successively rewiring their natural regulatory activities and seamless modification of various genes, this method would trigger T-cells to produce therapeutic proteins of interest in a strongly localized and controlled manner. 

Additionally, the company has changed the current T-cells into powerful and precise micro-robots which could spray IL-12 precisely onto cancer cells. This would prevent the potential toxicity of IL-12’s systemic injection while improving CAR-T activity.

Earlier this year, Cellectis had made headlines when it revealed that it has signed a manufacturing service agreement that covers clinical manufacturing of the company’s allogeneic UCART drug candidates pursuing hematological malignancies. 

Reportedly, the manufacturing is expected to be conducted at Lonza's GMP facility which is located in Geleen, Netherlands.

Source Credit: https://www.cellectis.com/en/press/cellectis-publishes-creation-of-smart-car-t-cells-for-potentially-safer-more-effective-treatments-for-cancer-in-nature-communications/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

By Mateen Dalal

Twitter, an American microblogging service company, had touted plans of acquiring Clubhouse, an audio chat iPhone app and live drop-in audio networking platform. The deal was estimated to be valued at around USD 4 billion, as per reliable sources. T...

Beyond Meat sets up factory in China to expedite localized innovation

Beyond Meat sets up factory in China to expedite localized innovation

By Mateen Dalal

American plant-based meat substitute producer Beyond Meat has opened a new production facility in China. Apparently, this recent setup is the company’s first facility outside the U.S., making it the only multinational organization solely focusi...